A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis

The New England Journal of Medicine
M LevineM Kovacs

Abstract

Patients with acute proximal deep-vein thrombosis are usually treated first in the hospital with intravenous standard (unfractionated) heparin. However, the longer plasma half-life, better bioavailability after subcutaneous administration, and more predictable anticoagulant response of low-molecular-weight heparins make them attractive for possible home use. We compared these two approaches. Patients with acute proximal deep-vein thrombosis were randomly assigned to receive either intravenous standard heparin in the hospital (253 patients) or low-molecular-weight heparin (1 mg of enoxaparin per kilogram of body weight subcutaneously twice daily) administered primarily at home (247 patients). The study design allowed outpatients taking low-molecular-weight heparin to go home immediately and hospitalized patients taking low-molecular-weight heparin to be discharged early. All the patients received warfarin starting on the second day. Thirteen of the 247 patients receiving low-molecular-weight heparin (5.3 percent) had recurrent thromboembolism, as compared with 17 of the 253 patients receiving standard heparin (6.7 percent; P=0.57; absolute difference, 1.4 percentage points; 95 percent confidence interval, -3.0 to 5.7). Five pati...Continue Reading

References

Apr 1, 1976·Circulation·J HirshW L Yung
Oct 1, 1992·Chest·M N LevineG Raskob
Nov 19, 1992·The New England Journal of Medicine·D P BrandjesJ W ten Cate
Sep 1, 1992·Thrombosis Research·M UdvardyK Rak
Feb 1, 1991·Práctica odontológica
May 30, 1991·The New England Journal of Medicine·J Hirsh
Feb 9, 1989·The New England Journal of Medicine·A W LensingH R Büller
Mar 27, 1995·Archives of Internal Medicine·A W LensingJ Hirsh

❮ Previous
Next ❯

Citations

Dec 1, 1996·Pharmacy World & Science : PWS·H ten CateJ W ten Cate
Nov 30, 1999·The International Journal of Angiology : Official Publication of the International College of Angiology, Inc·R R DaviesR J Gusberg
Jun 13, 2006·Canadian Journal of Anaesthesia = Journal Canadien D'anesthésie·Philippe de MoerlooseSerge Motte
Nov 15, 2002·International Journal of Hematology·Walter Ageno
Jul 21, 2010·Der Hautarzt; Zeitschrift für Dermatologie, Venerologie, und verwandte Gebiete·V MeyerT Görge
Sep 17, 2009·Der Orthopäde·L-C Linke
Jul 13, 2005·Cardiovascular and Interventional Radiology·Takuji YamagamiTsunehiko Nishimura
Feb 15, 2001·Cardiovascular and Interventional Radiology·M DelomezC Théry
Apr 4, 2008·European Radiology·A N KeelingM J Lee
Mar 6, 2007·Journal of Thrombosis and Thrombolysis·Thomas M HyersUNKNOWN INNOVATE Investigators
May 8, 2007·Journal of Thrombosis and Thrombolysis·Beste OzbenAhmet Oktay
Jul 25, 2009·Journal of Thrombosis and Thrombolysis·Frederick A SpencerRobert J Goldberg
Nov 30, 2000·Current Treatment Options in Cardiovascular Medicine·H Al-ZahraniJ I Weitz
Jun 29, 2013·Advances in Therapy·Thomas Vanassche, Peter Verhamme
May 14, 2005·Current Surgery·Eric J HanlyElizabeth A Mittendorf
Mar 26, 2004·Thrombosis Research·Jacqueline SawDavid J Moliterno
Sep 20, 1997·The American Journal of Cardiology·A G Turpie
Jun 23, 1999·The American Journal of Medicine·A S Dunn, B Coller
Nov 24, 1999·The American Journal of Medicine·R H WhiteP S Romano
Dec 22, 1999·Thrombosis and Haemostasis·C Kearon
Aug 23, 2001·Thrombosis Research·A Y Lee
Dec 4, 2003·Thrombosis Research·Philip C Comp
Feb 11, 2000·Thrombosis Research·W Ageno
Aug 5, 2000·Pharmacology & Therapeutics·R I Shulman
Aug 26, 1998·International Journal of Cardiology·G Agnelli, F Sonaglia
Nov 9, 2000·Archives of Medical Research·F López-JiménezG A Lamas
Jul 31, 2003·Cancer Treatment Reviews·Mark N Levine
Jan 5, 2002·Emergency Medicine Clinics of North America·D F Brown
Jul 1, 1997·The Journal of Emergency Medicine·G D InnesA Holmes
Aug 30, 2001·Critical Care Clinics·M T DeSancho, J H Rand

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.